Advocacy intelligence hub — real-time data for patient organizations
University of Massachusetts, Boston — PHASE2
Washington University School of Medicine — PHASE2
University of Maryland, Baltimore — PHASE2
Vanderbilt-Ingram Cancer Center — PHASE1
NYU Langone Health — PHASE1
Sichuan Enray Pharmaceutical Sciences Company — PHASE2
Fox Chase Cancer Center — PHASE1
UNC Lineberger Comprehensive Cancer Center — PHASE1
University Health Network, Toronto — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Blenoxane
(Bleomycin sulfate)Orphan drugstandardBristol-Myers Squibb Pharmaceutical Research Institute
Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the i...
Erbitux
(cetuximab)Orphan drugstandardImClone Systems Incorporated
Epidermal Growth Factor Receptor Antagonist [EPC]
12.1 Mechanism of Action The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane glycoprotein that is a member of a subfamily o...
KEYTRUDA
(pembrolizumab)Orphan drugstandardMSD International Business GmbH
Endoglycosidase [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytoki...
Sujith Baliga, M.D
Ohio State University Comprehensive Cancer Center
📍 COLUMBUS, OH
Douglas Adkins, MD
Washington University School of Medicine
📍 ANN ARBOR, MI
Julie E Bauman, M.D. MPH
NRG Oncology
📍 WASHINGTON, DC
Marcelo Bonomi, MD, MD
Wake Forest University Health Sciences
📍 COLUMBUS, OH
Mikhail Samsonov
R-Pharm
Daniel Ma
Mayo Clinic
View all Squamous cell carcinoma of head and neck specialists →